Compromised antigen presentation ranks among the top mechanisms that render cancers non-immunogenic (non-responsive to immune ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

Ethakota, J. , Singh, B. , Bai, S. , Tareen, H. , Kumar, D. and Malik, D. (2025) The Role of Artificial Intelligence in ...

In particular, T-cell engager bsAbs facilitate immune cell–mediated tumor destruction by linking T cells to tumor antigens. Instead, dual immune checkpoint inhibitors (CPIs) enhance immune activation ...

Data from a Phase I trial found it to be safe and well tolerated with early signs of clinical activity EPS 401 (formerly TIGA-001), an anti-EGFR IgA antibody with IND-enabling studies underway Further ...

One of the main challenges is the scarcity of truly cancer-specific antigens for precise targeting of solid tumors. The use of engineered small, specific antigen-binding domains, such as nanobodies, ...

A news release says NEC Corporation has developed and successfully demonstrated a facial recognition system for personalized cancer vaccine therapies. The firm says the biometric tool for the ...

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer ...

HealthDay News — Black and American Indian patients are less likely to have elevated cancer antigen (CA)-125 levels at ovarian cancer diagnosis, according to a study published in JAMA Network Open.

including non-small cell lung cancer and head and neck cancer. It utilizes mRNA encoding multiple TAAs encapsulated in a lipid nanoparticle (LNP) delivery system. Following intramuscular injection, ...

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...